178 related articles for article (PubMed ID: 30606771)
1. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ
Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771
[TBL] [Abstract][Full Text] [Related]
2. CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; Graña-Castro O; Pisano DG; Barrero MJ
Epigenetics Chromatin; 2018 Jun; 11(1):30. PubMed ID: 29884215
[TBL] [Abstract][Full Text] [Related]
3. Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming.
Ebrahimi A; Sevinç K; Gürhan Sevinç G; Cribbs AP; Philpott M; Uyulur F; Morova T; Dunford JE; Göklemez S; Arı Ş; Oppermann U; Önder TT
Nat Chem Biol; 2019 May; 15(5):519-528. PubMed ID: 30962627
[TBL] [Abstract][Full Text] [Related]
4. Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.
Brand M; Clayton J; Moroglu M; Schiedel M; Picaud S; Bluck JP; Skwarska A; Bolland H; Chan AKN; Laurin CMC; Scorah AR; See L; Rooney TPC; Andrews KH; Fedorov O; Perell G; Kalra P; Vinh KB; Cortopassi WA; Heitel P; Christensen KE; Cooper RI; Paton RS; Pomerantz WCK; Biggin PC; Hammond EM; Filippakopoulos P; Conway SJ
J Med Chem; 2021 Jul; 64(14):10102-10123. PubMed ID: 34255515
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.
Ghosh S; Taylor A; Chin M; Huang HR; Conery AR; Mertz JA; Salmeron A; Dakle PJ; Mele D; Cote A; Jayaram H; Setser JW; Poy F; Hatzivassiliou G; DeAlmeida-Nagata D; Sandy P; Hatton C; Romero FA; Chiang E; Reimer T; Crawford T; Pardo E; Watson VG; Tsui V; Cochran AG; Zawadzke L; Harmange JC; Audia JE; Bryant BM; Cummings RT; Magnuson SR; Grogan JL; Bellon SF; Albrecht BK; Sims RJ; Lora JM
J Biol Chem; 2016 Jun; 291(25):13014-27. PubMed ID: 27056325
[TBL] [Abstract][Full Text] [Related]
6. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
[TBL] [Abstract][Full Text] [Related]
7. CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells.
Bommi-Reddy A; Park-Chouinard S; Mayhew DN; Terzo E; Hingway A; Steinbaugh MJ; Wilson JE; Sims RJ; Conery AR
PLoS One; 2022; 17(3):e0262378. PubMed ID: 35353838
[TBL] [Abstract][Full Text] [Related]
8. MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors.
Furlan T; Kirchmair A; Sampson N; Puhr M; Gruber M; Trajanoski Z; Santer FR; Parson W; Handle F; Culig Z
Am J Pathol; 2021 Jun; 191(6):1094-1107. PubMed ID: 33705753
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain.
Denny RA; Flick AC; Coe J; Langille J; Basak A; Liu S; Stock I; Sahasrabudhe P; Bonin P; Hay DA; Brennan PE; Pletcher M; Jones LH; Chekler ELP
J Med Chem; 2017 Jul; 60(13):5349-5363. PubMed ID: 28375629
[TBL] [Abstract][Full Text] [Related]
12. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.
Boorjian SA; Heemers HV; Frank I; Farmer SA; Schmidt LJ; Sebo TJ; Tindall DJ
Endocr Relat Cancer; 2009 Mar; 16(1):123-37. PubMed ID: 18845648
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
14. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma.
Wei W; Song Z; Chiba M; Wu W; Jeong S; Zhang JP; Kadin ME; Nakagawa M; Yang Y
Leukemia; 2023 Feb; 37(2):396-407. PubMed ID: 36456744
[TBL] [Abstract][Full Text] [Related]
15. EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells.
Huttunen J; Aaltonen N; Helminen L; Rilla K; Paakinaho V
Cell Mol Life Sci; 2024 Apr; 81(1):160. PubMed ID: 38564048
[TBL] [Abstract][Full Text] [Related]
16. Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor.
Casaburi I; Cesario MG; Donà A; Rizza P; Aquila S; Avena P; Lanzino M; Pellegrino M; Vivacqua A; Tucci P; Morelli C; Andò S; Sisci D
Oncotarget; 2016 Mar; 7(11):12651-61. PubMed ID: 26862856
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.
Pérez-Peña J; Győrffy B; Amir E; Pandiella A; Ocaña A
Breast Cancer Res Treat; 2018 Dec; 172(3):725-732. PubMed ID: 30206781
[TBL] [Abstract][Full Text] [Related]
18. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
[TBL] [Abstract][Full Text] [Related]
19. Androgens induce divergent proliferative responses in human breast cancer cell lines.
Birrell SN; Bentel JM; Hickey TE; Ricciardelli C; Weger MA; Horsfall DJ; Tilley WD
J Steroid Biochem Mol Biol; 1995 May; 52(5):459-67. PubMed ID: 7748811
[TBL] [Abstract][Full Text] [Related]
20. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G
Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]